Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL

  • End date
    Jun 24, 2025
  • participants needed
  • sponsor
    Second Affiliated Hospital, School of Medicine, Zhejiang University
Updated on 4 October 2022
platelet count
ejection fraction
monoclonal antibodies
measurable disease
cell transplantation
neutrophil count
follicular lymphoma
cancer chemotherapy
diffuse large b-cell lymphoma
large b-cell lymphoma
anti-cd20 monoclonal antibody


To evaluate the safety and tolerability of CD19-CAR-DNT cells infusion in subjects with relapsed/refractory B-cell non-Hodgkin's Lymphoma


This is an open, single-arm, single-dose, dose-escalation and dose-expansion clinical trial designed to evaluate the maximum tolerated dose of CD19-CAR-DNT cells, the safety, the preliminary efficacy and the pharmacokinetic profile of CD19-CAR-DNT cells in vivo after infusion in clinical studies. 9 patients are planned to be enrolled in the dose-escalation trial (1×10^6 CD19-CAR-DNT cells/kg, 3×10^6 CD19-CAR-DNT cells/kg, 9×10^6 CD19-CAR-DNT cells/kg) and 3 patients in the dose-expansion trial. The primary endpoints are DLT, MTD, and the incidence of abnormalities in AE/SAE/AESI/laboratory tests/electrocardiograms/vital signs.

Condition B-cell Non-Hodgkin's Lymphoma
Treatment CD19-CAR-DNT cells
Clinical Study IdentifierNCT05453669
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Voluntarily sign an ICF and expect to complete the study procedures for follow-up examinations and treatment
Aged 18 to 75 years (including cut-offs), regardless of gender
A diagnosis of B-cell non-Hodgkin's lymphoma confirmed by cytology or pathological histology according to WHO 2016 criteria, including pathologically confirmed diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL) and high-grade B-cell lymphoma (HGBCL)
Relapsed/refractory B-cell non-Hodgkin's lymphoma, provided one of the following conditions is met
Subjects with B-cell non-Hodgkin's lymphoma who have failed at least second-line regimens (including relapse, non-remission, progression) and have received a standardised regimen of anti-CD20 monoclonal antibodies (except CD20-negative) and anthracyclines
Relapse after autologous haematopoietic stem cell transplantation
Primary resistance: induction with 2 courses of anti-CD20 monoclonal antibody-based immunochemotherapy at the time of first treatment, the best curative effect assessed as stable disease or disease progression
ECOG score 0 to 1
The presence of a measurable lesion that meets one of the following criteria
The long axis of the lymph node lesion exceeds 15 mm in length (the short axis is measurable)
The long and short axes of the extralymph node lesion exceed 10 mm in length
Appropriate organ function, with laboratory results within 7 days prior to lymphatic
clearance chemotherapy meeting the following criteria
Glutathione aminotransferase (AST) ≤ 3 times the upper limit of normal (ULN)
Glutamic aminotransferase (ALT) ≤ 3 times ULN
Total bilirubin ≤ 1.5 times ULN, unless the subject has documented Gilbert syndrome. Subjects with Gilbert-Meulengracht syndrome with total bilirubin ≤ 3.0 times ULN and direct bilirubin ≤ 1.5 times ULN may be included
Serum creatinine ≤ 1.5 times ULN or a creatinine clearance ≥ 60 ml/min
Haemoglobin ≥ 60 g/L or haemoglobin maintained at that level following transfusion
Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
A platelet count ≥ 30 x 10^9/L or a platelet count maintained at that level following a platelet transfusion
Left ventricular ejection fraction (LVEF) ≥ 45%
Female subjects with of childbearing potential should have a negative pregnancy test
during the screening period. Any male and female subjects of childbearing
potential must agree to use an effective contraception method for at least six
months from the time that they sign the informed consent form until the end of
the cell infusion. Female subjects without childbearing potential (meeting at
least 1 of the following criteria) is described below
Have undergone a hysterectomy or bilateral oophorectomy
Medically recognised ovarian failure
Medically recognised as post-menopausal (at least 12 consecutive months of menopause without pathological or physiological cause)

Exclusion Criteria

Other malignancies within 5 years prior to screening, except adequately treated carcinoma in situ of the cervix, basal cell or squamous epithelial cell skin cancer, post-radical localized prostate cancer, post-radical ductal carcinoma in situ, and post-radical thyroid cancer
Any unstable systemic disease: including but not limited to active infection (other than local infection), unstable angina, cerebrovascular accident or transient ischaemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), New York Heart Association class III or IV cardiac insufficiency, refractory hypertension (refractory hypertension is defined as blood pressure that has not reached standard after >1 month of reasonably tolerable treatment with ≥3 antihypertensive drugs (including diuretics) at adequate doses based on lifestyle improvement or blood pressure that is not effectively controlled with ≥4 antihypertensive drugs), severe cardiac arrhythmias requiring pharmacologic treatment, hepatic arrhythmias, liver diseases, kidney diseases or metabolic disorders
Patients with B-cell non-Hodgkin's lymphoma with active central nervous system invasion
Patients with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood hepatitis B virus (HBV) DNA titres not within the normal reference range, positive hepatitis C virus (HCV) antibody and peripheral blood HCV RNA ,positive for human immunodeficiency virus (HIV), or positive for cytomegalovirus (CMV) DNA, or positive syphilis test
Active or uncontrolled infections requiring systemic treatment (except simple urinary tract infections or upper respiratory tract infections)
Subjects who are receiving systemic steroids prior to screening and who are judged by the investigator to require long-term treatment with systemic steroids during the treatment period (except for inhaled or topical use)
Previous organ transplantation or preparation for organ transplantation (except for haematopoietic stem cell transplantation)
Persons with acute/chronic Graft-vs-Host Disease (GvHD)
Patients have received a haematopoietic stem cell transplant within 2 months prior to screening
Patients have received CAR-T therapy or other gene-modified cell therapy prior to enrolment
Active neurological autoimmune or inflammatory diseases (e.g. Guillain-Barre Syndrome (GBS), Amyotrophic lateral sclerosis (ALS)) and clinically significant active cerebrovascular disease (e.g. cerebral oedema, Posterior Reversible Encephalopathy Syndrome (PRES)). Encephalopathy Syndrome (PRES))
Patients with a life expectancy of less than 3 months
Patients have been involved in other clinical studies within 3 months prior to screening
Patients, in the judgement of the investigator and/or clinical criteria, are contraindicated to any study procedure or have other medical conditions that may place them at unacceptable risk
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note